Improved Targeting of Pancreatic Cancer
- 15 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (10) , 3552-3561
- https://doi.org/10.1158/1078-0432.ccr-03-0340
Abstract
Purpose: The early detection and diagnosis of pancreatic cancer remains a major clinical challenge in which imaging procedures have a central role. The purpose of this study was to evaluate a pretargeting method with a bispecific PAM4 (bsPAM4; anti-MUC1) antibody for radioimmunoscintigraphy of experimental human pancreatic cancer. Experimental Design: A bispecific F(ab′)2 antibody was generated from chimeric PAM4 Fab′ and murine 734 (anti-indium-diethylenetriaminepentaacetic acid) Fab′ fragments and then used in conjunction with 2 peptide haptens (111In-IMP-156 and 99mTc-IMP-192). Biodistribution studies and radioimmunoscintigraphic imaging properties of the radiolabeled bsPAM4, and pretargeted, radiolabeled peptides were examined in the CaPan1 human pancreatic tumor grown as s.c. xenografts in athymic nude mice. Tumor uptake and tumor:nontumor ratios were compared with a nontargeting irrelevant anti-CD20, bispecific rituximab, radiolabeled peptides alone, and with directly labeled PAM4. Results: Biodistribution results indicated significantly greater tumor uptake of radiolabeled peptides at 3 h after injection when pretargeting was performed with bsPAM4 as compared with the bispecific rituximab [20.2 ± 5.5 percentage of injected dose per gram of tissue (%ID/g) versus 0.9 ± 0.1%ID/g, respectively, for 111In-IMP-156, and 16.8 ± 4.8%ID/g versus 1.1 ± 0.2%ID/g, respectively, for 99mTc-IMP-192]. Similar results were obtained at the 24-h time point. Tumor:nontumor ratios were >30 for all of the tissues except the kidneys, where a ratio of 7.8 ± 2.8 was observed. By immunoscintigraphy, tumors could be visualized as early as 30 min after injection of the radiolabeled peptide. Conclusions: These studies demonstrate the feasibility of using the pretargeted, bispecific antibody technology for nuclear imaging of pancreatic cancer. The advantage of pretargeted bsPAM4 antibody as an imaging platform is the high specificity for pancreatic cancer as compared with the physicochemical parameters identified by current imaging technologies.Keywords
This publication has 58 references indexed in Scilit:
- 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignanciesGut, 2003
- Radioimmunoscintigraphy in Patients with Ovarian CancerActa Oncologica, 2001
- Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA × Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled PeptideBioconjugate Chemistry, 2000
- Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas.American Journal of Roentgenology, 1999
- Efficacy of Monoclonal Antibody 131I-B72.3 Immunoscintigraphy of Pancreatic Adenocarcinoma Xenografts in Nude MiceThe European Journal of Surgery, 1999
- Radioimmunoscintigraphy in Patients with Ovarian CancerActa Oncologica, 1999
- 90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution StudiesBioconjugate Chemistry, 1998
- CD22 as target molecule for radioimmunodetection and radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic lecukemia and Waldenstromʼs macroglobulinemiaNuclear Medicine Communications, 1997
- A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium(III)Bioconjugate Chemistry, 1991
- A Method of Trace Iodination of Proteins for Immunologic StudiesInternational Archives of Allergy and Immunology, 1966